BillionToOne Targets Over $2 Billion Valuation in U.S. IPO
Molecular diagnostics company BillionToOne is preparing to go public in the U.S., aiming for a valuation of up to $2.42 billion. Based in Menlo Park, California, the firm plans to offer up to 3.8 million shares at a price range of $49 to $55 each, raising as much as $211.5 million. BillionToOne develops advanced disease-diagnostic…